Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets
Report Highlights
The global market for gastrointestinal disorder therapeutics and diagnostics reached $49.6 billion in 2015. This market is expected to grow from nearly $51.8 billion in 2016 to $63.8 billion in 2021 at a compound annual growth rate of 4.3% from 2016-2021.
Report Includes
- An overview of the global markets for gastrointestinal therapeutics and diagnostics.
- Analyses of global market trends, with data from 2015, estimates for 2016, and projections of CAGRs through 2021.
- Analyses of therapeutics currently on the market as well as potential products and classes of products that are likely to have a significant impact.
- Descriptions of the industry in detail, its relationship to the healthcare industry, its participants, and its trends for the future.
- Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities.
- Profiles of major players in the industry.
SCOPE OF REPORT
This report is designed to provide an in-depth look at the therapeutic and diagnostic options of various gastrointestinal disorders. The geographic scope of the report is global, with particular emphasis on the key markets such as the U.S. and the European Union Five (EU5). The estimated market data is also global in nature, with geographic segments such as the U.S., EU and Rest of the World (ROW). The report provides a brief overview of the gastrointestinal system, which provides an introduction to the disorders of the gastrointestinal system; cites risk factors, where applicable; presents current pharmaceutical treatments, market size and key market participants (both prescription and OTC); and presents potential treatments in R&D, potential market size and future market entrants.
As already mentioned, the market for gastrointestinal pharmaceuticals is divided into two general segments: prescription gastrointestinal pharmaceuticals and OTC gastrointestinal pharmaceuticals. Similarly, the market for gastrointestinal diagnostics, testing and vaccines is divided into three general segments:
- Diagnostics and testing market.
- Medical devices (endoscopy)
- Vaccines.
The market is further broken down into the drugs to treat specific disorders within the gastrointestinal system, including the following:
- Gastrointestinal tract disorders.
- Gastrointestinal tract walls disorders.
- Gastrointestinal motility disorders.
- Gastrointestinal cancers.
Each sub-segment is covered in detail, describing the disorders and diseases, identifying currently available and potential products, and competitors.
Frequently Asked Questions (FAQs)
Analyst Credentials
Yogita Zutshi has worked in clinical operations and market research in pharmaceuticals, including the development of training in pharmacovigilance. She studies products, markets and regulatory environments. She holds a bachelor's degree in education, and master's degrees in clinical research and organic chemistry from Cranfield University.
Report Highlights
- Overall sales in the gastrointestinal disorder treatment market amounted to $34.2 billionin 2007, and decreased slightly to $31.1 billion in 2009. By 2014, they are projected to reach $32.2 billion, for a 5-year compound annual growth rate (CAGR) of 0.7%.
- The largest segment of the market, prescription gastrointestinal drugs, was valued at $27.4 billion in 2008; this is expected to decrease to $26,3 billion in 2009, and to reach $27 billion in 2014, for a 5-year CAGR of 0.5%.
Report Highlights
-
The total U.S. market for gastrointestinal disorder treatments was estimated at $16.1 billion for 2004. Rising at an AAGR (average annual growth rate) of 7.3%, the market is expected to reach $22.8 billion in 2009.
-
The prescription market accounted for the largest percentage of sales with approximately 85%, or $13.7 billion in sales in for 2004. This segment is also rising the fastest, with an AAGR of 7.7%.
-
The OTC market accounts for the remaining 15%, or $2.4 billion. Rising at AAGR of 14%, it will represent only 13% of the market in 2009.
-
At approximately 80%, the largest area of market participation for leading competitors is within the prescription drug segment.